Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
PHOTREXA VISCOUS is a riboflavin 5-phosphate ophthalmic solution used in corneal cross-linking procedures to strengthen corneal tissue and halt progressive keratoconus. Administered as topical drops prior to UV-A light exposure, it acts as a photosensitizer to create covalent bonds within collagen. The product is indicated for patients with progressive corneal ectasia seeking to preserve vision and delay or prevent corneal transplantation.
Peak-stage product at Glaukos with moderate competitive pressure (30/100), suggesting stable commercial operations but not aggressive growth phase expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PHOTREXA VISCOUS offers stable career positioning in the niche specialty ophthalmology space with direct patient impact through vision-preservation outcomes. Peak-stage lifecycle suggests mature team dynamics focused on market maintenance and procedure-center relationships rather than high-growth scaling.
Worked on PHOTREXA VISCOUS IN DEXTRAN 20% at Glaukos? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.